Malfunctions and adverse events associated with off-label use of biliary stents in the peripheral vasculature

American Journal of Therapeutics

Volumn 15, Issue 1, 2008, Pages 12-18

  Bridges, Jonathan ^a   Maisel, William H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Percutaneous intervention; Peripheral arterial disease; Public health; Regulatory affairs; Stent

Indexed keywords

ALLERGY; ARTICLE; BLEEDING; BLOOD VESSEL INJURY; BLOOD VESSEL PERFORATION; CATHETER COMPLICATION; CONTROLLED STUDY; DEVICE INFECTION; DEVICE REMOVAL; ENDOVASCULAR SURGERY; FALSE ANEURYSM; FOOD AND DRUG ADMINISTRATION; HEART INJURY; HEPATOBILIARY SYSTEM; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; PAIN; PERIPHERAL VASCULAR SYSTEM; PRIORITY JOURNAL; STENT; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

BILE DUCTS; HUMANS; PERIPHERAL VASCULAR DISEASES; PRODUCT LABELING; PRODUCT SURVEILLANCE, POSTMARKETING; STENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38549169721     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31815fa6f2     Document Type: Article

References (23)

1. Cavanaugh KJ. Evaluation of renal artery stenting. Endovasc Today. 2006;September:105-107.
2. Winstein KJ. FDA contests biliary stent marketing. Wall Street Journal. March15, 2007:D9.
3. Winstein KJ. FDA to review uses of bile-duct stents. Wall Street Journal. March12, 2007:A3.
4. Abel DB. Off-label medical device use. Endovasc Today. 2003;2:60-61.
5. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aorta): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease). Circulation. 2006;113:e463-e654.
6. Hirsch AT. Treatment of peripheral arterial disease - extending 'intervention' to 'therapeutic choice.' N Engl J Med. 2006;354:1944-1947.
7. AlMahameed A, Bhatt DL. Contemporary management of peripheral arterial disease: III. Endovascular and surgical management. Cleve Clin J Med. 2006;73:S45-S51.
8. Criado FJ. Editor's Corner: on the approval and use of vascular devices: what's in a label? Vascular Disease Management. 2007;4:A2-A4.
9. Product Classification Database. U.S. Food and Drug Administration web site. Available at: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/ classification.cfm?ID=1561. Accessed May 16, 2007.
10. Manufacturer and User Facility Device Experience Database (MAUDE). U.S. Food and Drug Administration web site. Available at: www.fda.gov/cdrh/maude. html. Accessed May 16, 2007.
11. Biliary Stent Market in: U.S. Markets for Nonvascular Stents 2007. Toronto: Millenium Research Group; 2007:26-34.
12. Form 10-K: U.S. Securities and Exchange Commission Annual Report, ev3 Inc. 2006. U.S. Securities and Exchange Commissionweb site. Available at:www.sec.gov/Archives/edgar/data/1318310/000110465907019126/a07-5880_110k.htm. Accessed May 16, 2007.
13. U.S. Markets for Peripheral Vascular Stents. Report A250. Newport Beach, CA: Medtech Insight; 2006. Available at: www.medtechinsight.com/ReportA250.html. Accessed May 16, 2007.
14. Wright C. The rise and rise of stents. Scrip Magazine. 2006; January:10-13.
15. Form 10-K: U.S. Securities and Exchange Commission Annual Report, Boston Scientific Corporation 2006. U.S. Securities and Exchange Commission web site. Available at: www.sec.gov/Archives/edgar/data/885725/000107261307000570/form10- k_14949.htm#ITEM6. Accessed May 26, 2007.
16. Form 10-K: U.S. Securities and Exchange Commission Annual Report, Abbott Laboratories 2006. U.S. Securities and Exchange Commission web site. Available at:www.sec.gov/Archives/edgar/data/1800/000110465907013496/a07-1583_110k.htm. Accessed May 16, 2007.
17. Muradin GSR, Bosch JL, Stijnen T, et al. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221:137-145.
18. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888.
19. Maisel WH. Medical device regulation: an introduction for the practicing physician. Ann Intern Med. 2004;140:296-302.
20. Maisel WH. Unanswered questions-drug-eluting stents and the risk of late thrombosis: N Engl J Med. 2007;356:981-984.
21. Surowiec SM, Davies MG, Eberly SW, et al. Percutaneous angioplasty and stenting of the superficial femoral artery. J Vasc Surg. 2005;41:269-278.
22. Conrad MF, Cambria RP, Stone DH, et al. Intermediate results of percutaneous endovascular therapy of femoropoliteal occlusive disease: a contemporary series. J Vasc Surg. 2006;44:762-769.
23. Maisel WH, Laskey WK. Patent foramen ovale closure devices: moving beyond equipoise. JAMA. 2005;294:366-369.